In 2014 the Eight Joint Nation Committee (JNC-8) established goals for hypertension management. Clinicians should indirectly monitor the therapeutic index through blood pressure control and evaluation for side effects. Typically well-tolerated mild side effects have been previously reported, including but not limited to dizziness, headache, drowsiness, nausea, vomiting, diarrhea, and electrolyte disturbances, for instance, hyperkalemia.****When discontinuing olmesartan, recommendations for other antihypertensive medications be considered according to provider preference to maintain blood pressure goals established in JNC-8.

Renal function tests (CrCl) and liver function may require monitoring as dose adjustments may be necessary in cases of significant renal impairment, guidelines for which appear below.

A complete metabolic panel can also help monitor any possible derangement of potassium, sodium, calcium, chloride, magnesium, phosphate, and magnesium.

Monitor for diarrhea and weight as there is potential for olmesartan-associated enteropathy.